PATENT COOPERATION TREATY

Comman S	EG			WIE	Allements (
		2	3	2003 j	Same of the same o

From the INTERNATIONAL SEARCHING AUTHORITY

To: HISCOCK & BARCLAY, LLP Attn. Womer, Jason R. 2000 HSBC Plaza 100 Chestnut Street Rochester, NY 14604-2404 ETATS-UNIS D'AMERIQUE

PCT

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT AND THE WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY, OR THE DECLARATION

(PCT Rule 44.1) Date of mailing (day/month/year) 29/06/2009 Applicant's or agent's file reference FOR FURTHER ACTION See paragraphs 1 and 4 below 3009040 WO02 International application No. International filing date (day/month/year) 07/01/2008 PCT/US2008/050375 Applicant FXS VENTURES, LLC

1. X	The applicant is hereby notified that the international search report and the written opinion of the International Search Authority have been established and are transmitted herewith.						
	Filling of amendments and statement under Article 19:						

When? The time limit for filing such amendments is normally two months from the date of transmittal of the

International Search Report. Where? Directly to the International Bureau of WIPO, 34 chemin des Colombettes

1211 Geneva 20, Switzerland, Fascimile No.: (41-22) 338.82.70 For more detailed instructions, see the notes on the accompanying sheet,

The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect and the written opinion of the International Searching Authority are transmitted herewith.

With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices. no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. Reminders

Shortly after the expiration of 18 months from the priority date, the International application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

The applicant may submit comments on an informal basis on the written opinion of the International Searching Authority to the International Bureau. The International Bureau will send a copy of such comments to all designated Offices unless an international preliminary examination report has been or is to be established. These comments would also be made available to the public but not before the expiration of 30 months from the priority date.

Within 19 months from the priority date, but only in respect of some designated Offices, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later); otherwise, the applicant must, within 20 months from the priority date, perform the prescribed acts for entry into the national phase before those designated Offices.

In respect of other designated Offices, the time limit of 30 months (or later) will apply even if no demand is filed within 19 months.

See the Annex to Form PCT/fB/301 and, for details about the applicable time limits, Office by Office, see the PCT Applicant's Guide, Volume II, National Chapters and the WIPO Internet site.

Name and mailing address of the International Searching Authority



European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk

Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Fax: (+31-70) 340-3016

Authorized officer

Andrea Oberhauser

NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the *PCT Applicant's Guide*, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative instructions, respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report and the written opinion of the International Searching Authority, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only (see *PCT Applicant's Guide*, Volume I/A, Annexes B1 and B2).

The attention of the applicant is drawn to the fact that amendments to the claims under Article 19 are not allowed where the International Searching Authority has declared, under Article 17(2), that no international search report would be established (see *PCT Applicant's Guide*, Volume I/A, paragraph 296).

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the international Bureau and not with the receiving Office or the international Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the International application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

- [Where originally there were 48 claims and after amendment of some claims there are 51]:
 "Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
- [Where originally there were 15 claims and after amendment of all claims there are 11]: "Claims 1 to 15 replaced by amended claims 1 to 11."
- 3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]; "Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or "Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
- [Where various kinds of amendments are made]:
 "Claims 1–10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international application is to be published.

It must be brief, not exceeding 500 words it in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. If must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments and any accompanying statement, under Article 19. a demand for international preliminary examination has already been submitted, the applicant must preferably, at the time of filing the amendments (and any statement) with the international Bureau, also file with the International Preliminary Examining Authority a copy of such amendments (and of any statement) and, where required, a translation of such amendments for the procedure before that Authority (see Rules 55.3(a) and 62.2, first sentence). For further information, see the Notes to the demand form (PCT/IPEA/401).

If a demand for international preliminary examination is made, the written opinion of the International Searching Authority will, except in certain cases where the International Preliminary Examining Authority did not act as international Searching Authority and where it has notified the International Bureau under Rule 66.1bis(b), be considered to be a written opinion of the international Preliminary Examining Authority. If a demand is made, the applicant may submit to the International Preliminary Examining Authority a reply to the written opinion together, where appropriate, with amendments before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later (Rule 43bis.1(c)).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see the PCT Applicant's Guide, Volume II.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER see Form PCT/ISA/220					
3009040 WOO2	ACTION as well	as, where applicable, Item 5 below.				
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)				
PCT/US2008/050375	07/01/2008	05/01/2007				
Applicant						
FXS VENTURES, LLC						
PAS VENTORES, LLC						
This international search report has been according to Article 18. A copy is being tra	prepared by this international Searching Authorsmitted to the International Bureau.	ority and is transmitted to the applicant				
This international search report consists of	of a total of5sheets.					
X It is also accompanied by	a copy of each prior art document cited in this	report.				
Basis of the report						
military.	international search was carried out on the ba					
	application in the language in which it was filed e international application into					
of a translation fu	rnished for the purposes of international searc	h (Rules 12.3(a) and 23.1(b))				
b This international search authorized by or notified t	report has been established taking into accour o this Authority under Rule 91 (Rule 43.6 <i>bis</i> (a	nt the rectification of an obvious mistake				
c. With regard to any nucle	otide and/or amino acid sequence disclosed	in the international application, see Box No. I.				
2. Certain claims were fou	nd unsearchable (See Box No. II)					
3. Unity of invention is lac	king (see Box No III)					
4. With regard to the title,						
X the text is approved as su	ibmitted by the applicant					
the text has been establis	shed by this Authority to read as follows:					
5. With regard to the abstract,						
X the text is approved as su	ubmitted by the applicant					
the text has been establis may, within one month from	shed, according to Rule 38.2(b), by this Authori om the date of mailing of this international sear	ty as It appears in Box No. IV. The applicant ch report, submit comments to this Authority				
With regard to the drawings,						
	oublished with the abstract is Figure No.					
as suggested by						
	is Authority, because the applicant failed to su					
	is Authority, because this figure better characte	erizes the invention				
b none of the figures is to b	e published with the abstract					

International application No PCT/US2008/050375

a. classification of subject matter INV. A61L12/14 C11D3 C11D3/00 C11D3/32 C11D3/33 C11D3/34 C11D3/37 According to international Patent Classification (IPC) or to both national classification and IPC Minimum documentation searched (classification system followed by classification symbols) A61L C11D Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. χ US 2006/148665 A1 (SMITH FRANCIS X [US]) 1 - 146 July 2006 (2006-07-06) Υ page 1, paragraphs 6,7 1 - 14page 1, paragraph 12 - page 2, paragraph claims 1-7 χ WO 02/062260 A (BIO CONCEPT LAB [US]; 1 - 14SMITH FRANCIS XAVIER [US]) 15 August 2002 (2002-08-15) claims 1-7 Υ page 3 - page 6 1 - 14χ Further documents are listed in the continuation of Box C. See patent family annex. Special categories of cited documents: *T* later document published after the international filing date or priority date and not in conflict with the application but clied to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance invention earlier document but published on or after the international "X" document of particular refevance; the claimed invention cannot be considered novel or cannot be considered to filing date 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) involve an inventive step when the document is taken alone *Y* document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docudocument referring to an oral disclosure, use, exhibition or ments, such combination being obvious to a person skilled document published prior to the international filing date but later than the priority date claimed *&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 15 June 2009 29/06/2009 Name and mailing address of the ISA/ Authorized officer European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016 Romano-Götsch, R

International application No
PCT/US2008/050375

(Continua	tion). DOCUMENTS CONSIDERED TO BE RELEVANT	
itegory*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 93/04706 A (ALLERGAN INC [US]) 18 March 1993 (1993-03-18) page 6, lines 7-30 page 10, line 16 - page 11, line 35 examples 1-3 claims 7,19	12,13
X	US 2003/190258 A1 (SMITH FRANCIS X [US]) 9 October 2003 (2003-10-09) page 5 - page 6; examples 8-10	12,13
K Y	JP 2006 089403 A (FUJITA HIRONORI; SENJU PHARMA CO) 6 April 2006 (2006-04-06)	12,13
	see also English automatic translation from JPO website: http://dossierl.ipdl.inpit.go.jp paragraphs [0040] - [0042]; examples 7,8	1-14
X	JP 08 152584 A (ASAHI CHEMICAL IND) 11 June 1996 (1996-06-11) abstract	12,13
(WO 02/38161 A (BIO CONCEPT LAB [US]; SMITH FRANCIS XAVIER [US]) 16 May 2002 (2002-05-16) page 1 - page 2; claims	12,13
r	GB 1 431 841 A (EVANS S C) 14 April 1976 (1976-04-14) page 2, lines 30-76; claim 1	12,13
), X	US 2007/104744 A1 (SMITH FRANCIS X [US]) 10 May 2007 (2007-05-10) page 1, paragraph 13 - page 2, paragraph 21 claims 1-12	1-14
	WO 2008/077110 A (FXS VENTURES LLC [US]; SMITH FRANCIS X [US]) 26 June 2008 (2008-06-26) page 2, paragraphs 6,7 page 4, paragraph 15-19 claims 1-14	1-14
		<u>.</u>

Information on patent family members

International application No PCT/US2008/050375

	ient document In search report		Publication date		Patent family member(s)	Publication date
us	2006148665	A1	06-07-2006	NONE		
MO	02062260	A	15-08-2002	AT	406167 T	15-09-2008
				AT	405265 T	15-09-2008
				AU	2595002 A	21-05-2002
				AU	3954502 A	27-05-2002
				AU	2002225950 B2	10-08-2006
				AU	2002239545 B2	05-10-2006
				AU	2002251685 B2	27-10-2005
				CA	2428994 A1	15-08-2002
				ČA	2428997 A1	23-05-2002
				CA	2434961 A1	16-05-2002
				CN	1486186 A	31-03-2004
	•			CN	1505520 A	16-06-2004
	•			CN	1486187 A	31-03-2004
				DK	1337262 T3	15-12-2008
				DK	1331902 T3	08-12-2008
				EP	1337262 A2	27-08-2003
				EP	1339414 A2	03-09-2003
				EP	1331902 A2	06-08-2003
				EP	1992340 A1	19-11-2008
				ES	2311555 T3	16-02-2009
				ES	2311035 T3	01-02-2009
				JP	2004512901 T	30-04-2004
				JP	2004525865 T	26-08-2004
				JP	2004526186 T	26-08-2004
				PT	1337262 E	24-10-2008
				PT	1331902 E	02-12-2008
				WO	0238077 A2	16-05-2002
2000 taken separa se				WO	0240062 A2	23-05-2002
WO 9	9304706	Α	18-03-1993	AT	156367 T	15-08-1997
				AU	653432 B2	29-09-1994
				AU	2557392 A	05-04-1993
				CA DE	2095022 A1	01-03-1993
				DE	69221463 D1	11-09-1997
					69221463 T2	05-03-1998
				DE DK	555464 T1	15-02-1996
				EP EP	555464 T3 0555464 A1	09-02-1998
				ES	2106882 T3	18-08-1993
				FI	931940 A	16-11-1997
				GR	3024488 T3	29-04-1993
				HU	64240 A2	28-11-1997
				IL	102905 A	28-12-1993
				JP	6501643 T	14-11-1996 24-02-1994
				JP	3234600 B2	24-02-1994 04-12-2001
				JP	3904851 B2	11-04-2007
				ĴΡ	2002082055 A	22-03-2002
				KR	100256116 B1	01-06-2000
				MX	9204912 A1	01-02-1993
	•			NO	931571 A	29-04-1993
				NZ	243749 A	25-11-1994
				PL	² 299186 A1	27-12-1993
		•		PL	172353 B1	30-09-1997
				PT	100825 A	28-02-1994
				RU	2114638 C1	10-07-1998
				US	5578240 A	26-11-1996
				0.5	2270240 K	ZU-11-144L

Information on patent family members

International application No PCT/US2008/050375

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 9304706	Α		ZA	9206522	A	28-04-1993
US 2003190258	A1	09-10-2003	NONE	ر <u>سیر بیش باشد فقات باید</u> نیوی جمعه محدد خصه محدد		dere verer heren Stein's Liville Stales Stein- 1994, gjelle halde unsge Verste steine steine stein
JP 2006089403	A	06-04-2006	NONE	manifer manifer manifer (1964) after a state and an angele manifer estates and	OLDAN JAMAN PROCESS SARSIN WARREN	mere metten danske belgen untere untere 1998 i Hand utvår menne pelem steller neden utveke (1995
JP 8152584	Α	11-06-1996	JP	3442168	B2	02-09-2003
WO 0238161	Α	16-05-2002	AU AU CA CN EP JP JP	2720602 2002227206 2428985 1486188 1339418 4084997 2004512904	B2 A1 A A1 B2	21-05-2002 21-09-2006 16-05-2002 31-03-2004 03-09-2003 30-04-2008 30-04-2004
GB 1431841	A	14-04-1976	NONE		27-75-76 HENRY WHICH SAME SEASON SAME	an and the state and the state state and the state of the state and the
US 2007104744	A1	10-05-2007	WO	2008086270	A2	17-07-2008
WO 2008077110	A	26-06-2008	US	2007098818	A1	03-05-2007

PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY To: WRITTEN OPINION OF THE see form PCT/ISA/220 INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1) Date of mailing (day/month/year) see form PCT/ISA/210 (second sheet) Applicant's or agent's file reference FOR FURTHER ACTION see form PCT/ISA/220 See paragraph 2 below International application No. International filing date (day/month/year) Priority date (day/month/year) PCT/US2008/050375 07.01.2008 05.01.2007 International Patent Classification (IPC) or both national classification and IPC INV. A61L12/14 C11D3/00 C11D3/32 C11D3/33 C11D3/34 C11D3/37 Applicant **FXS VENTURES, LLC** This opinion contains indications relating to the following items: Box No. 1 Basis of the opinion Box No. II Priority ☐ Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability ☐ Box No. IV Lack of unity of invention Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement Box No. VI Certain documents cited Box No. VII Certain defects in the international application Box No. VIII Certain observations on the international application 2. **FURTHER ACTION** If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notifed the International Bureau under Rule 66.1 bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. For further details, see notes to Form PCT/ISA/220. Name and mailing address of the ISA: Date of completion of Authorized Officer this opinion European Patent Office see form Romano-Götsch, R PCT/ISA/210

Telephone No. +49 89 2399-8874

D-80298 Munich Tel. +49 89 2399 - 0

Fax: +49 89 2399 - 4465

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/US2008/050375

-							
-	Bo	x No	o. I Basis of the opinion				
1.	Wit	With regard to the language, this opinion has been established on the basis of:					
	\boxtimes	the	international application in the language in which it was filed				
		a t pu	ranslation of the international application into , which is the language of a translation furnished for the rposes of international search (Rules 12.3(a) and 23.1 (b)).				
2.		Th by	is opinion has been established taking into account the rectification of an obvious mistake authorized or notified to this Authority under Rule 91 (Rule 43bis.1(a))				
3.	Wit nec	h re ess	gard to any nucleotide and/or amino acid sequence disclosed in the international application and ary to the claimed invention, this opinion has been established on the basis of:				
	a. t	ype	of material:				
			a sequence listing				
	I		table(s) related to the sequence listing				
	b. fo	orma	at of material:				
	[on paper				
			in electronic form				
	c. ti	ime ·	of filling/furnishing:				
	I		contained in the international application as filed.				
	[filed together with the international application in electronic form.				
	[furnished subsequently to this Authority for the purposes of search.				
4.		cop	addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto be been filed or furnished, the required statements that the information in the subsequent or additional bies is identical to that in the application as filed or does not go beyond the application as filed, as propriate, were furnished.				
5.	Add	lition	nal comments:				

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/US2008/050375

Box No. II Priority

- 1.

 The validity of the priority claim has not been considered because the International Searching Authority does not have in its possession a copy of the earlier application whose priority has been claimed or, where required, a translation of that earlier application. This opinion has nevertheless been established on the assumption that the relevant date (Rules 43bis.1 and 64.1) is the claimed priority date.
- 2.

 This opinion has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid (Rules 43*bis*.1 and 64.1). Thus for the purposes of this opinion, the international filing date indicated above is considered to be the relevant date.
- 3. Additional observations, if necessary:

see separate sheet

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

No: Claims

1-14

Inventive step (IS)

Yes: Claims

No: Claims

1-14

Industrial applicability (IA)

Yes: Claims

1-14

No: Claims

2. Citations and explanations

see separate sheet

Box No. VI Certain documents cited

 Certain published documents (Rules 43bis.1 and 70.10) and /or

2. Non-written disclosures (Rules 43bis.1 and 70.9)

see form 210

NRITTEN OPINION OF THE NTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/US2008/050375

				application

The following defects in the form or contents of the international application have been noted:

see separate sheet

Re Item II.

For a valid claim to priority, the application the priority of whose filing date is claimed must be the first application that has been filed for the invention. A subsequent application for the same subject-matter as the previous application filed for the same State is considered as the first application for priority purposes if, when this subsequent application is filed, the first application had been withdrawn, abandoned or refused without being open to public inspection or without leaving any rights outstanding, and has not served as basis for claiming priority (Art. 8(1)PCT; Rule 4.10 PCT). In the present case, at the date of filing US 2007/104744 A1 (D9) (which is claimed as priority by the present application), the application corresponding to US 2006/148665 A1 (D1) has not been withdrawn, abandoned or refused.

It follows that present subject-matter of claims 1-14 (namely claims 1-11, part of claims 12-13, and claim 14) that has been already disclosed in document D1 is not entitled to the claimed priority. For said subject-matter, D1 and D9 form prior art according to Art.33 (2) and Rule 33.1 PCT.

The additional subject-matter disclosed in claims 12-13 is rightly claims D9 as priority document.

Re Item V.

Reference is made to the following documents:

D1: US 2006/148665 A1

D2: WO 02/062260 A

D3: WO 93/04706 A

D4: US 2003/190258 A1

D5: JP 2006 089403 A

D6: JP 08 152584 A

D7: WO 02/38161 A

D8: GB 1 431 841 A

D9: US 2007/104744 A1 (2007-05-10)

The presently claimed matter 1-14 lacks novelty in the sense of Art.33(2) PCT, as being anticipated by the following documents:

Documents D1 (claims 1-7), **D2** (claims 1-7) and **D9** (par.6-7) disclose a contact lenses solution comprising **0.001**% of a preservative enhancer chosen from the group consisting of thiamine (B1), riboflavin (B2), niacin (B3), pantothenic acid (B5), pyridoxine (B6), and cobalamin (B12); and at least 0.0001 weight percent of a cationic polymeric preservative and a concentration of 0.2 or less percent chloride, and the

same additives claimed in the application.

D1 (par.12-14) and D2 (pp.3-4) further disclose contact lens solutions comprising **0.0001%** to about 1.0% of one of the vitamin B forms chosen from the group consisting of thiamine (B1), riboflavin (B2), niacin (B3), **panthenol** (B5), pyridoxine (B6), and cobalamin (B12), **folic acid, carnitine, inositol.**

It follows that D1, D2 and D9 are novelty destroying for claims 1-14.

The following documents anticipate the novelty of claims 12-13.

Document D3 (see passages cited in the search report) discloses a contact lens solution comprising vitamin B12 in the form of cyanocobalamin or cobalamin or derivatives such as methyl-, hydroxy- or desoxyadenoxsyl-cobalamin.

Document D4 (see in particular examples 8-10) discloses several solutions for storing, rinsing and disinfecting contact lenses comprising inositol and choline. Thus, D4 anticipates the novelty of claims 12-13.

Document D5 discloses (examples 7-8) eye drops for contact lens removal comprising pyridoxine hydrochloride.

Document D6 discloses a contact lens solution comprising one or more compounds selected from pyridoxine hydrochloride, cyanocobalamin, flavine adenine dinucleotide sodium(FAD).

Document D7 discloses (p.2) a contact lens solution comprising inositol.

In view of the outstanding novelty objections, an inventive step cannot be acknowledged for claims 1-14 (Art.33 (3) PCT).

Re Item VI

WO2008/077110 A published on 26.06.2008, with an international filing date of 19.12.2007 and claiming a priority date of 19.12.2006.

Re Item VII

The expression "Vitamin B Complex" does not have a defined meaning and renders the scope of claims 12 and 13 unclear (Art. 6 PCT).

Claim 13 contains several repetitions: some names are repeated more than once (e.g., thiamine, folic acid); furthermore the vitamins <u>as well as the corresponding compounds</u> (e.g. vitamin B-1 is thiamin, vitamin B-2 is riboflavin) are recited in the claim. Consequently, claim 13 is unclear and lacks of conciseness.

Possible steps after receipt of the international search report (ISR) and written opinion of the International Searching Authority (WO-ISA)

General information

For all international applications filed on or after 01/01/2004 the competent ISA will establish an ISR. It is accompanied by the WO-ISA. Unlike the former written opinion of the IPEA (Rule 66.2 PCT), the WO-ISA is not meant to be responded to, but to be taken into consideration for further procedural steps. This document explains about the possibilities.

Art. 19 PCT

Amending claims Within 2 months after the date of mailing of the ISR and the WO-ISA the applicant may file amended claims under Art. 19 PCT directly with the International Bureau of WIPO. The PCT reform of 2004 did not change this procedure. For further information please see Rule 46 PCT as well as form PCT/ISA/220 and the corresponding Notes to form PCT/ISA/220.

Filing a demand for international preliminary examination

In principle, the WO-ISA will be considered as the written opinion of the IPEA. This should, in many cases, make it unnecessary to file a demand for international preliminary examination. If the applicant nevertheless wishes to file a demand this must be done before expiry of 3 months after the date of mailing of the ISR/WO-ISA or 22 months after priority date, whichever expires later (Rule 54bis PCT). Amendments under Art. 34 PCT can be filed with the IPEA as before, normally at the same time as filing the demand (Rule 66.1 (b) PCT).

If a demand for international preliminary examination is filed and no comments/amendments have been received the WO-ISA will be transformed by the IPEA into an IPRP (International Preliminary Report on Patentability) which would merely reflect the content of the WQ-ISA. The demand can still be withdrawn (Art. 37 PCT).

Filing informal comments

After receipt of the ISR/WO-ISA the applicant may file informal comments on the WO-ISA directly with the International Bureau of WIPO. These will be communicated to the designated Offices together with the IPRP (International Preliminary Report on Patentability) at 30 months from the priority date. Please also refer to the next box.

End of the international phase

At the end of the international phase the International Bureau of WIPO will transform the WO-ISA or, if a demand was filed, the written opinion of the IPEA into the IPRP, which will then be transmitted together with possible informal comments to the designated Offices. The IPRP replaces the former IPER (international preliminary examination report).

Relevant PCT Rules and more information.

Rule 43 PCT, Rule 43bis PCT, Rule 44 PCT, Rule 44bis PCT, PCT Newsletter 12/2003, OJ 11/2003, OJ 12/2003

EUROPEAN PATENT OFFICE

Patent Abstracts of Japan

PUBLICATION NUMBER

2006089403

PUBLICATION DATE

06-04-06

APPLICATION DATE

22-09-04

APPLICATION NUMBER

2004276179

APPLICANT: SENJU PHARMACEUT CO LTD;

INVENTOR: AKI HIROSHI;

INT.CL.

: A61K 9/08 (2006.01), A61K 45/00 (2006.01), A61P 27/02 (2006.01), G02C 13/00

(2006.01)

TITLE

: OPHTHALMIC COMPOSITION FOR TAKING OUT CONTACT LENS

ABSTRACT :

PROBLEM TO BE SOLVED: To obtain an ophthalmic composition for enabling a contact lens to be easily taken out without adding excessive force and without using tools such as

a sucker and a dropping pipet even if the contact lens adheres to the eye.

SOLUTION: This ophthalmic composition for taking out the contact lens is an aqueous composition having 0.01-0.12 or 0.29-0.56 ion strength, and preferably further contains at least one kind of medicinal component selected from a cornea-protecting agent, vitamins

and amino acids.

COPYRIGHT: (C)2006,JPO&NCIPI

EUROPEAN PATENT OFFICE

Patent Abstracts of Japan

PUBLICATION NUMBER

08152584

PUBLICATION DATE

11-06-96

APPLICATION DATE

30-11-94

APPLICATION NUMBER

06296077

APPLICANT: ASAHI CHEM IND CO LTD;

INVENTOR: IKETANI TOMOJI;

INT.CL.

G02C 13/00

TITLE

: CARE ARTICLE

ABSTRACT :

PURPOSE: To improve fitting feeling of contact lens by dipping a contact lens in a soln.

prepared by compounding one or more compds. selected from among pyrioxine

hydrochloride, cyanocobalamin, etc.

CONSTITUTION: A soln. is prepared by compounding one or more compds. selected from among pyridoxine hydrochloride, cyanocobalamin, flavine adenine dinucleotide sodium(FAD). It is preferable to control the compounding amt. of these compds. to obtain 0.001-10% concn. in the soln, when a contact lens is dipped. If the amt, of these compd. is less than 0.0001%, the desired effect is hardly obtd. If the amt. exceeds 10%, an increase in the effect is not obtd. By this method, fitting feeling of a contactlens can be improved.

COPYRIGHT: (C)1996, JPO